AZD7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model

被引:71
作者
Goldstein, RN
Khrestian, C
Carlsson, L
Waldo, AL
机构
[1] Case Western Reserve Univ, Univ Hosp Cleveland, Div Cardiol, MS LKS 5038, Cleveland, OH 44106 USA
[2] AstraZeneca R&D, Molndal, Sweden
关键词
atrial fibrillation; atrial flutter; antiarrhythmic drug;
D O I
10.1046/j.1540-8167.2004.04354.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New Atrial Antiarrhythmic Drug. Introduction: We tested the hypothesis that AZD7009 terminates induced atrial fibrillation (AF) and flutter (AFL) and prevents their reinduction, and that effects on refractoriness, conduction, and excitability are predominantly on the atria. Methods and Results: Thirty-eight electrophysiologic studies were performed during AZD7009 infusion in 11 dogs with sterile pericarditis. The effects of AZD7009 on refractoriness, conduction, and capture threshold were studied and its antiarrhythmic efficacy tested. Simultaneous multisite biatrial mapping was performed in 7 dogs to assess arrhythmia termination. AZD7009 prolonged arrhythmia cycle length (CL) from 121 +/- 7.8 to 157 +/- 9.7 msec (P < 0.001) before terminating 23 of 23 AF/AFL episodes. Mapping demonstrated that AF/AFL CL prolonged and then terminated in area(s) of slow conduction in a reentrant circuit. Arrhythmia reinduction failed in 19 of 20 attempts. At 400-msec CL, atrial and ventricular refractoriness and QT interval increased 33%, 17% (P < 0.001 vs atrial refractoriness), and 9%, respectively. Atrial capture threshold increased in a CL-dependent manner: 1.8 +/- 0.3 to 2.2 +/- 0.3 mA (CL 400 msec); 2.1 +/- 0.3 to 2.8 +/- 0.5 mA (CL 300 msec), and 2.2 +/- 0.3 to 5.3 +/- 0.8 mA (CL 200 msec). Only minor nonsignificant changes occurred in the ventricles: 0.95 +/- 0.05 to 0.98 +/- 0.06 mA (CL 400 msec), and 1.14 +/- 0.12 to 1.16 +/- 0.13 mA (CL 333 msec). Atrial conduction time increased 8 +/- 1.4 msec (CL 400 msec), 8.3 +/- 1.5 msec (CL 300 msec), and 13.2 +/- 1.6 msec (CL 200 msec, all P < 0.001), but ventricular conduction time was unchanged. Conclusion: AZD7009 is highly efficacious in terminating AF/AFL and preventing reinduction in this model. It exhibits marked effects on atrial electrophysiology but has only modest effects on the ventricle.
引用
收藏
页码:1444 / 1450
页数:7
相关论文
共 13 条
[1]  
Duker G, 2004, HEART RHYTHM, V1, pS159
[2]  
Goldstein RN, 2003, CIRCULATION, V108, P708
[3]   HUMAN VENTRICULAR REFRACTORINESS - EFFECTS OF INCREASING CURRENT [J].
GREENSPAN, AM ;
CAMARDO, JS ;
HOROWITZ, LN ;
SPIELMAN, SR ;
JOSEPHSON, ME .
AMERICAN JOURNAL OF CARDIOLOGY, 1981, 47 (02) :244-250
[4]  
Kumagai K, 1997, CIRCULATION, V95, P511
[5]   DATA ACQUISITION-SYSTEM FOR CARDIAC MAPPING [J].
LAURITA, K ;
THOMAS, CW ;
KAVURU, M ;
VESSELLE, H ;
LIEBMAN, J .
PROCEEDINGS OF THE ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, PTS 1-4, 1988, :104-105
[6]  
LAURITA K, 1989, P IEEE ENG MED BIOL, P204
[7]  
LINHARDT G, 2004, EUR HEART J, V6, P2939
[8]   MECHANISM OF INTERRUPTION OF ATRIAL-FLUTTER BY MORICIZINE - ELECTROPHYSIOLOGICAL AND MULTIPLEXING STUDIES IN THE CANINE STERILE PERICARDITIS MODEL OF ATRIAL-FLUTTER [J].
ORTIZ, J ;
NOZAKI, A ;
SHIMIZU, A ;
KHRESTIAN, C ;
RUDY, Y ;
WALDO, AL .
CIRCULATION, 1994, 89 (06) :2860-2869
[9]   A NEW ANIMAL-MODEL OF ATRIAL-FLUTTER [J].
PAGE, PL ;
PLUMB, VJ ;
OKUMURA, K ;
WALDO, AL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (04) :872-879
[10]  
PERSSON F, 2000, IN PRESS J CARDIOVAS